APRE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AP

Volume

156.26K

Next Earnings

November 11th

Loading chart

AP

APREAprea Therapeutics, Inc. Common stock

APRE

Pay with—

Available Balance0.00

AP

Mkt Cap

$7.8M

Volume

156.26K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceAprea Therapeutics, a clinical-stage precision medicine oncology company, announced that its President and CEO Oren Gilad will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026. The company is developing targeted cancer therapies including APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development for solid tumors.GlobeNewswire Inc. · Sep 10, 2026

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer CenterAprea Therapeutics reported positive preclinical and early-stage clinical data for its next-generation WEE1 inhibitor, APR-1051, in treating HPV-positive head and neck squamous cell carcinoma. The drug showed potent single-agent activity and enhanced synergy with anti-PD-1 therapies in preclinical models, and demonstrated early disease control in a Phase 1 trial.GlobeNewswire Inc. · Jun 25, 2025

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical UpdateAprea Therapeutics reported progress in its clinical trials for ATRN-119 and APR-1051, with early evidence of anti-tumor activity and continued enrollment. The company has sufficient cash runway into early Q2 2026.GlobeNewswire Inc. · May 14, 2025

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscapeGlobeNewswire Inc. · Jun 21, 2024

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitorGlobeNewswire Inc. · Jun 17, 2024

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical TrialATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potentialGlobeNewswire Inc. · May 28, 2024

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare ConferenceDOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that management will attend the 2024 RBC Capital Markets Global Healthcare Conference that will take place May 14-15, 2024 in New York, NY. Details are as follows:GlobeNewswire Inc. · May 13, 2024

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovationGlobeNewswire Inc. · May 2, 2024

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancersGlobeNewswire Inc. · Apr 10, 2024

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateFirst-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024GlobeNewswire Inc. · Mar 26, 2024

to start trading

AP

APREAprea Therapeutics, Inc. Common stock

APRE

Pay with—

Available Balance0.00

Your PositionYou don't own any APRE yet.

Related Tickers

Earnings